As many as 15% of all ICU admissions are a result of ARDS or ARDS related symptoms. It carries as high as a 50% mortality rate. This kind of result is unparalleled and highlights a therapy that entirely changes the game. We look forward to the results of the Phase 3 trial with great anticipation.
Excited to announce our phase 2 RCT results in #ARDS #extracellularvesicles significantly decreased #mortality ...team effort with our clinical sites across the country, dedicated #physicians and #pulmonologists and #scientists to move #regenerativemedicine forward into the clinic https://lnkd.in/gQt5fKZq